Clinical Trials Browser

Phase 3 × dostarlimab × Thoracic × Clear all

NCT04655976 2025-09-26

COSTAR Lung

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06472076 2025-09-10

A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung